Answers are grounded in this paper and cite their sources.
Background Eftrenonacog alfa is an extended half-life recombinant factor IX Fc fusion protein (rFIXFc) approved for the treatment and prevention of bleeding episodes in people with hemophilia B (PwHB). Providing continuous and comprehensive real-world data is crucial to support informed treatment strategies with rFIXFc in routine practice. The B-MORE study was designed to provide further insights into real-world utilization and effectiveness of rFIXFc in PwHB. Objectives To describe the final real-world effectiveness and usage data for rFIXFc in PwHB from B-MORE. Design B-MORE (NCT03901755) was a 24-month prospective, non-interventional study across Europe and the Middle East. Eligible patients had hemophilia B and started rFIXFc treatment before or at enrollment, regardless of study participation. Methods Descriptive analyses were performed for patients who received ≥6 months of rFIXFc prophylaxis, either during the prospective period or since rFIXFc initiation (before/at enrollment). Additionally, intrapatient comparisons with prior standard half-life (SHL) FIX prophylaxis were conducted. Endpoints included annualized bleeding rate (ABR), injection frequency, factor consumption, and treatment satisfaction. Results B-MORE enrolled 151 patients from 29 centers; >80% completed the study. In the prospective period (N=137), median (interquartile range)/mean ABR was low at 0.5 (0.0–1.2)/0.9. Median (interquartile range) injection frequency and factor consumption were also low with 52.5 (52.2–52.6) injections/year and 2,443 (2,022–2,970) IU/kg/year, respectively. Results were similar since rFIXFc initiation (N=137). Compared to prior SHL prophylaxis (N=92), ABR was reduced/remained low, while injection frequency and factor consumption reduced since rFIXFc initiation. Most physicians (88.5%; 69/78) and patients (90.0%; 90/100) were satisfied/highly satisfied with rFIXFc prophylaxis. Conclusions B-MORE represents the largest real-world investigation of rFIXFc usage, with up to nearly seven years of follow-up (retrospective and prospective periods). Final data confirm rFIXFc as an effective and well-tolerated long-term prophylactic treatment for hemophilia B.
No takes yet. Share an insight, caveat, or question.
Glosli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: